Immunic Stock Quote Today

IMUX -  USA Stock  

USD 8.47  0.04  0.47%

Immunic is trading at 8.47 as of the 21st of October 2021; that is 0.47 percent up since the beginning of the trading day. The stock's open price was 8.43. Immunic has 49 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Immunic are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 21st of September 2021 and ending today, the 21st of October 2021. Click here to learn more.
 Market Performance
0 of 100
  Odds Of Distress
Less than 49
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. t and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. The company has 21.75 M outstanding shares of which 962.43 K shares are currently shorted by private and institutional investors with about 5.04 trading days to cover. More on Immunic

Immunic Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Immunic's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Immunic or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Immunic generated a negative expected return over the last 90 days
Immunic has high historical volatility and very poor performance
Immunic was previously known as Vital Therapies and was traded on NMS Exchange under the symbol VTL.
Net Loss for the year was (76.54 M) with loss before overhead, payroll, taxes, and interest of (4.91 K).
Immunic currently holds about 87.17 M in cash with (67.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.32.
Immunic has a very weak financial position based on the latest SEC disclosures
Roughly 25.0% of the company shares are held by company insiders
Latest headline from Immunic gains 3.34 percent on Moderate Volume October 15 -
Immunic Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Immunic SEC Filings
Immunic SEC Filings Security & Exchange Commission EDGAR Reports
Legal NameImmunic
Older SymbolVTL
President CEO, DirectorDaniel Vitt  (View All)
Average Analyst Recommendation
Analysts covering Immunic report their recommendations after researching Immunic's financial statements, talking to executives and customers, or listening in on Immunic's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Immunic. The Immunic consensus assessment is calculated by taking the average forecast from all of the analysts covering Immunic.
Strong Buy9 Opinions
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Immunic based on its profitability, leverage, liquidity, source of funds, and operating efficiency. it is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Immunic financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 1 - Very WeakDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares16.9 M15.7 M
Significantly Up
Slightly volatile
Weighted Average Shares Diluted16.9 M15.7 M
Significantly Up
Slightly volatile
Total Assets181.1 M167.9 M
Significantly Up
Slightly volatile
Total Liabilities12.8 M9.1 M
Significantly Up
Slightly volatile
Current Assets105.9 M133.7 M
Significantly Down
Slightly volatile
Current Liabilities8.2 M8.4 M
Fairly Down
Slightly volatile
Total Debt704.4 K679 K
Sufficiently Up
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Immunic's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Financial Strength
Immunic's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Immunic's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Immunic's financial leverage. It provides some insight into what part of Immunic's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Immunic's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Immunic deploys its capital and how much of that capital is borrowed.
Immunic cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 1.02 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Immunic has a current ratio of 6.88, suggesting that it is liquid enough and is able to pay its financial obligations when due.

Operating Cash Flow

(49.77 Million)Share
Immunic (IMUX) is traded on NASDAQ Exchange in USA. It is located in 1200 Avenue of the Americas and employs 45 people. Immunic was previously known as Vital Therapies and was traded on NMS Exchange under the symbol VTL. Immunic is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 184.65 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Immunic's market, we take the total number of its shares issued and multiply it by Immunic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Immunic conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 21.75 M outstanding shares of which 962.43 K shares are currently shorted by private and institutional investors with about 5.04 trading days to cover. Immunic currently holds about 87.17 M in cash with (67.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.32.
Check Immunic Probability Of Bankruptcy
Immunic secures a total of 21.75 Million outstanding shares. Immunic secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Immunic Ownership Details

Immunic Stock Price Odds Analysis

What are Immunic's target price odds to finish over the current price? Based on a normal probability distribution, the odds of Immunic jumping above the current price in 90 days from now is about 83.4%. The Immunic probability density function shows the probability of Immunic stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.0949. This usually indicates Immunic market returns are sensitive to returns on the market. As the market goes up or down, Immunic is expected to follow. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Immunic is significantly underperforming DOW.
 Odds Down 8.47HorizonTargetOdds Up 8.47 
16.49%90 days
Based on a normal probability distribution, the odds of Immunic to move above the current price in 90 days from now is about 83.4 (This Immunic probability density function shows the probability of Immunic Stock to fall within a particular range of prices over 90 days) .

Immunic Historical Income Statement

Immunic Income Statement is one of the three primary financial statements used for reporting Immunic's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Immunic revenue and expense. Immunic Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Immunic Selling General and Administrative Expense is fairly stable at the moment as compared to the past year. Immunic reported Selling General and Administrative Expense of 10.33 Million in 2020. Weighted Average Shares is likely to rise to about 16.9 M in 2021, whereas Consolidated Income is likely to drop (47.5 M) in 2021. View More Fundamentals

Immunic Stock Against Markets

Picking the right benchmark for Immunic stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Immunic stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Immunic is critical whether you are bullish or bearish towards Immunic at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Immunic without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now


Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Immunic Corporate Directors

Immunic corporate directors refer to members of an Immunic board of directors. The board of directors generally takes responsibility for the Immunic's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Immunic's board members must vote for the resolution. The Immunic board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Jorg Neermann - DirectorProfile
Jan Bossche - DirectorProfile
Randolph Steer - Independent DirectorProfile
Vincent Ossipow - DirectorProfile
Please see Risk vs Return Analysis. Note that the Immunic information on this page should be used as a complementary analysis to other Immunic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Immunic Stock analysis

When running Immunic price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Equity Search
Search for activelly traded equities including funds and ETFs from over 30 global markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Transaction History
View history of all your transactions and understand their impact on performance
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
CEO Directory
Screen CEOs from public companies around the world
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine Immunic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.